Work Here?
Overview
Company Does Not Provide H1B Sponsorship
Earli develops a cancer diagnostics platform that uses synthetic biology to create Synthetic Bioclassifiers. These genetic constructs enter cells and, if a cell is cancerous, activate and cause the cancer cell to produce a biomarker released into the bloodstream. The biomarker enables detection of cancer at very early stages by making cancer cells reveal themselves, addressing limitations of traditional liquid biopsies. The system is programmable to distinguish cancerous from healthy cells and is designed for partnerships with healthcare providers and pharmaceutical companies to commercialize the platform, with Accenture supporting its strategy.
About Earli
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
Get referred to Earli
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 14, 2026 Earli said $104M total funding after another $44M round.
- Australian sites in Sydney, Melbourne, Frankston, and Adelaide now recruit trial patients.
- Accenture Ventures, a16z, Khosla, and Perceptive back Earli's current push.
What critics are saying
- Phase 1 safety and pharmacodynamics determine whether EARLI-001 survives 2026.
- Metastatic patient enrollment limits signal quality and delays broad early-detection validation.
- If synthetic biomarkers fail in humans, Earli becomes another Stanford lab curiosity.
What makes Earli unique
- Earli's synthetic bioclassifiers make cancer cells secrete biomarkers, unlike passive liquid biopsies.
- Stanford-origin platform targets early detection and treatment with one programmable construct.
- August 2026 Australia phase 1 trial tests lung and metastatic liver biomarkers first.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$59.5M
Above
Industry Average
Funded Over
2 Rounds
Andreessen Horowitz
Menlo VenturesIndustry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 2%Earli, a startup founded by Cyriac Roeding, Dr. David Suhy, and the late Dr. Sanjiv Sam Gambhir, has raised $60 million to advance its cutting-edge cancer detection and treatment technology. The company engineers synthetic biomarkers within cancer cells, enabling earlier and more accurate detection and treatment. Following six years of research, Earli is preparing for human clinical trials, starting with lung cancer, and aims to expand its platform to other cancer types.
GLIN Impact Capital 有限責任事業組合のプレスリリース（2024年10月31日 12時10分）GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資
Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company.
Earli, the company pioneering a new approach to cancer diagnostics by forcing cancer cells to produce synthetic biomarkers, announced today that Maggie Louie accepted the roll of Vice President of Biology.
When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples.
Earli is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Earli
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
Earli is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today